Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, today announced its mRNA drug discovery partnership with University Health Network (UHN), ranked first on a list of Canada's top 40 research hospitals by R
Pharmaceutical and biotech companies from Korea will be attending the “2023 Bio International Convention” held in Boston, Massachusetts, the U.S., from June 5 to 8. The convention is the largest biotech and pharmaceutical exhibition in the world and is organized by the Biotechnology Innovative Organ
Yuhan Corporation announced on May 30 that it has signed a technology licensing agreement with J INTS BIO for the tyrosine kinase inhibitor (TKI) “JIN-A04” targeting HER2.The total contract size amounts to 429.8 billion won (US$325.8 million), inclusive of an upfront payment of 25 billion won (US$19
The author is an analyst for Shinhan Securities. He can be reached at jaewonjeong@shinhan.com -- Ed.Pharmaceutical/bio sector to rebound in 2H23 on favorable macro conditions and progress in new drug pipelinesPharmaceutical/bio stocks have fallen out of investors’ favor with valuations declining on
The Korea Advanced Institute of Science and Technology (KAIST) announced on May 8 that a KAIST research team led by Professor Jung In-kyung of the School of Life Sciences has created the world’s first single-cell three-dimensional epigenome map of Parkinson’s disease-onset brain tissue and proposed
Daewoong Pharmaceutical announced that it signed an agreement to license its autoimmune disease drug candidate DWP213388 to Vitalli Bio, a subsidiary of Aditum Bio, a U.S. biotech investment company, at the Korea-U.S. Digital and Bio-health Business Forum held in Boston, the United States, on April
On April 20, Dong-A ST announced the results of a preclinical study of its immuno-oncology drug candidate “DA-4505” at the American Association for Cancer Research (AACR) 2023 held in Orlando, Florida in the United States from April 14 to 19.At this meeting, Dong-A ST presented the anti-tumor effect
Daewoong Pharmaceutical announced on April 18 that it has signed an open collaboration agreement with Signature Discovery, a global new drug development company, to discover effective substances for new drugs for autoimmune diseases.Through this agreement, the two companies will utilize Signature’s
SK Plasma will build a 300-billion-won blood plant in Indonesia. The plant will be capable of producing 1 million liters of blood products per year. The company plans to break ground on the plant in 2023 and complete it two years later.According to industry sources on March 7, SK Plasma has recently
Daewoong Pharmaceutical's botulinum toxin “Nabota” (export name: Nuceiva) obtained approval from Australia on Jan. 13, the company announced on Jan. 25.Nabota has been approved in 61 countries around the world, including Australia. Now Daewoong aims to make its botulinum toxin available in more
Protium Science, a contract development and analysis organization (CDAO) in Korea, announced that it has signed a contract development and analysis service agreement with MUSTBIO, a biotechnology company specializing in multi-specific antibody platforms.Under the agreement, Protium Science, as a CDA
LifeSemantics, a Korean company specializing in digital therapeutics (DTx), will unveil Redpill Breath, a digital therapeutics (DTx) for patients requiring pulmonary rehabilitation, at CES 2023, which will be held in Las Vegas in January 2023.LifeSemantics will participate in the Digital Healthcare
The authors are analysts of Shinhan Securities. They can be reached at sehunjang@shinhan.com and shawn1225@shinhan.com, respectively. -- Ed. Time to price in the value of next-generation FcRn inhibitorHanall Biopharma’s recent share price trend suggests that the removal of uncertainty in the clinica
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. In 2022, healthcare stocks have been performing sluggishly in the NY stock market, affected by drastic absorption of market liquidity since early-2022. Given that 10-yr discounted cash flow is the mo
An increasing number of orphan drugs developed by South Korean companies are entering the U.S. market, where more incentives are given to such drugs than in South Korea.Examples of such drugs recently approved by the U.S. FDA include MedPacto’s Vactosertib, HLB Therapeutics’ RGN-259, Hanmi Pharmaceu
JW Group announced on Nov. 1 that it has signed a joint research contract with KURE.AI Therapeutics, a U.S. biotech venture company, to develop innovative anticancer therapies based on artificial intelligence (AI).Under this contract, JW Pharmaceutical and JW CreaGene will start R&D activities for t
SK Inc.’s pharmaceutical and bio business is growing fast through a steady localization strategy. The company plans to expand its contract development and manufacturing organization (CDMO) business to cover cell and gene therapies (CGTs).SK Pharmteco, a CDMO subsidiary of SK Inc., is expected to rac
EOFlow Co., a provider of wearable drug delivery systems (DDS), announced on Oct. 24 that it would invest 36.9 billion won in its U.S. subsidiary EOFlow, Inc.The majority of this investment in EOFlow, Inc., approximately 31 billion won, will be used for collecting loans given by EOFlow to its U.S. s
The authors are analysts of Shinhan Investment Corp. They can be reached at sehunjang@shinhan.com and shawn1225@shinhan.com, respectively. -- Ed. 3Q22 preview: OP to miss market consensus due to cost hikesFor 3Q22, we now expect Daewoong Pharmaceutical to post standalone sales in line with market co
Chong Kun Dang has entered the cell and gene therapy market in earnest. The drugmaker opened a gene therapy research center on Sept. 27 and unveiled a plan to strengthen open innovation with domestic and foreign companies.The new research center is dubbed "Gen2C," which stands for "Gene to Cure." Th